MLYS NASDAQ
Mineralys Therapeutics, Inc.
1W: +10.8%
1M: +4.5%
3M: +8.4%
YTD: -15.3%
1Y: +87.8%
3Y: +93.2%
$29.85
-0.38 (-1.26%)
Weekly Expected Move ±8.2%
$23
$25
$27
$30
$32
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (55)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA
Mineralys (MLYS) Q1 2026 Earnings Transcript
Earnings Scheduled For May 6, 2026
Mineralys Therapeutics GAAP EPS of -$0.47 misses by $0.02
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Rating of “Moderate Buy” by Analysts
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares
Mineralys Therapeutics (NASDAQ:MLYS) Director Ra Capital Management, L.P. Buys 310,700 Shares
Mineralys Therapeutics Target of Unusually Large Options Trading (NASDAQ:MLYS)
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives $49.14 Consensus Target Price from Analysts
HC Wainwright Issues Optimistic Forecast for MLYS Earnings
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
What is HC Wainwright’s Forecast for MLYS FY2029 Earnings?
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP
Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy
Mineralys (MLYS) Q4 2025 Earnings Call Transcript
Mineralys Therapeutics GAAP EPS of -$0.40 beats by $0.13
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Earnings Scheduled For March 12, 2026
Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS
Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS
Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Mineralys Therapeutics, Inc. $MLYS Stake Boosted by American Century Companies Inc.
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Citigroup Inc.
Stock Traders Purchase Large Volume of Mineralys Therapeutics Call Options (NASDAQ:MLYS)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS)
Dow Eyes Best Day in 10 Months as Tech Rebound Lifts Sentiment
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $252,469.75 in Stock
Adam Scott Levy Sells 10,758 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Jon Congleton Sells 16,236 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
SG Americas Securities LLC Sells 23,950 Shares of Mineralys Therapeutics, Inc. $MLYS
David Malcom Rodman Sells 70,037 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Average Recommendation of “Moderate Buy” by Brokerages
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)